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Acquisition of Pneumocystis jirovecii infection early in
life has been confirmed by serologic studies. However, no
evidence of clinical illness correlated with the primary infec-
tion has been found in immunocompetent children. We
analyzed 458 nasopharyngeal aspirates from 422 patients
hospitalized with 431 episodes of acute respiratory tract
infection (RTI) by using a real-time PCR assay. In 68
episodes in 67 infants, P. jirovecii was identified. The odds
ratio (95% confidence interval) of a positive signal com-
pared with the first quartile of age (7–49 days) was 47.4
(11.0–203), 8.7 (1.9–39.7), and 0.6 (0.1–6.7) for infants in
the second (50–112 days), third (113–265 days), and fourth
(268–4,430 days) age quartiles, respectively. Infants with
an episode of upper RTI (URTI) were 2.0 (1.05–3.82) times
more likely to harbor P. jirovecii than infants with a lower
RTI. P. jirovecii may manifest itself as a self-limiting URTI in
infants, predominantly those 1.5–4 months of age.
T
he opportunistic fungus Pneumocystis jirovecii (for-
merly  Pneumocystis carinii f.sp.  hominis [1]) may
cause severe pneumonia (PCP) in patients with AIDS and
other immunodeficiencies. The epidemiology of P.
jirovecii infection is still not well understood, however.
Serologic studies have shown that children are exposed to
P. jirovecii early in life (2–5).
To our knowledge, no previous evidence exists of a
correlation between clinical illness and primary infection in
the competent host (6). Recently, P. jirovecii has been found
in respiratory secretions from infants with respiratory tract
infection (RTI) as well as in autopsy lung tissue from
infants who died of sudden infant death syndrome (7–10).
The role of a human reservoir for the pathogen, con-
sisting of HIV-positive or HIV-negative adults, has recent-
ly been debated (11). Also, immunocompetent children
may contribute to the circulation of the organism. In addi-
tion, detecting abundant infection in infants could reflect
widespread exposure from an environmental reservoir.
We conducted a blinded, retrospective study to deter-
mine the prevalence of P. jirovecii harbored in the respira-
tory tracts of Danish children with acute RTI, and whether
clinical and laboratory characteristics separate those with
and without P. jirovecii infection. The detection method
employed was a single-round, closed-tube, real-time PCR
assay. The study was approved by the Ethical Committee
of Copenhagen (KF 01–028/03).
Methods
Patient Population and Samples
All available routine nasopharyngeal aspirates (NPAs)
obtained for respiratory syncytial virus (RSV) analysis
during 1999–2002 from children hospitalized at the
Departments of Pediatrics, Hvidovre University Hospital
and Amager Hospital, Copenhagen, Denmark, were
included in the study. Thus, included samples and subjects
were NPAs from children in whom the treating physician
suspected or wished to rule out an RSV infection.
Therefore, most children were <24 months of age.
Samples collected within 3 weeks from the same person
were regarded as being from the same episode of respira-
tory disease.
Clinical Data Collection 
Clinical data were obtained by reviewing medical
records of the patients using uniform data abstraction
forms. The reviewer, a pediatrician, was blinded to PCR
data. A diagnosis of lower RTI (LRTI), upper RTI (URTI),
or “other” was made on the basis of recorded clinical find-
ings (12). In brief, a diagnosis of URTI was made if the
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*Hvidovre University Hospital, Copenhagen, Denmarkinfant had one or more of the following clinical signs with-
out evidence of LRTI: cough, nasal discharge, a red
bulging tympanic membrane, and pharyngotonsillar ery-
thema or exudate. A diagnosis of LRTI was made if the
infant also had abnormal sounds on lung auscultation and
chest indrawing or tachypnea. Infants with an RTI who
were hospitalized primarily for other reasons received the
diagnosis “other.”
PCR Analysis 
All samples were extracted and assayed in the Clinical
Microbiology Laboratory at Hvidovre University Hospital.
Universal PCR laboratory procedures were used, such as
physical separation of the steps involved in PCR and uni-
directional workflow; specimens were processed carefully
with observance of universal PCR laboratory precautions.
In addition, a single-round, nonnested, closed-tube PCR
assay, with no manipulations of amplicons required, inher-
ently reduces the risks of carryover contamination. To fur-
ther reduce this risk, uracil-N-glycosylase and
deoxyuridine triphosphate were used to prevent amplicon
carryover (13). PCR analysis was carried out with
researchers blinded to all clinical data. The code was only
broken at the time PCR analysis and clinical data collec-
tion were completed.
DNA Extraction 
DNA was extracted from patient and control speci-
mens with the automated MagnaPure (Roche Diagnostics
GmbH, Mannheim, Germany) system, using the MagNA
Pure LC DNA Kit III (bacteria, fungi) (Roche), according
to the manufacturer’s recommendations. A sample volume
of 100 µLwas used for extraction, and a preincubation step
was carried out by adding lysis buffer and protein K mix-
ture to the sample, which was then incubated for 15 min at
65°C, followed by 10 min at 95°C. Extracted material was
stored at −80°C.
PCR Controls 
P. jirovecii–positive and –negative respiratory sam-
ples, as determined by results of previous microscopy and
PCR, were included with each DNAextraction and in each
PCR run as external controls. An internal control amplifi-
able by the P. jirovecii primers was included to detect PCR
inhibitors in the patient specimens (14).
The following standards were set. For Pneumocystis,
10-fold serial dilutions (10−2–105 copies/µL) of a plasmid
containing a P. jirovecii major surface glycoprotein (MSG)
gene insert were prepared (14). Standard curves for quan-
tification of positive patient samples were generated by
assaying the serial dilution in triplicate. For betaglobin, 10-
fold serial dilutions (1.5 × 10−4–1.5 × 101 ng/µL) of human
genomic DNA provided with the Control Kit DNA
(Roche) were used to generate standard curves, according
to the manufacturer’s instructions.
DNA amplification and detection were carried out as
follows. For Pneumocystis, we used a quantitative touch-
down PCR method that targeted the multicopy MSG gene
of P. jirovecii (14). In brief, primers JKK14/15 and JKK17
amplify a 250-bp segment of the multicopy MSG gene
family. The MSG primers also amplify a 295-bp fragment
of the artificially constructed internal control. Detection
was carried out by using 2 separate sets of fluorescence
resonance energy transfer (FRET) probes, which detected
the MSG (PCMSGFRET1U and PCMSGFRET1D) and
internal control target (PCMIM1U and PCMIM1D),
respectively. The probes were labeled with Red640 and
Red705, respectively, for simultaneous amplification and
detection to take place in the same reaction tube. PCR con-
ditions were as previously described (14). First, all sam-
ples were assayed with the internal control included. P.
jirovecii–positive samples were then assayed for quantifi-
cation without an internal control, including 2 standards
(103 copies/µL) in the experiment, and the generated exter-
nal standard curve was imported for quantification.
For betaglobin, a commercial kit, Control Kit DNA
(Roche), was used to estimate the amount of human DNA
present in the samples. PCR conditions were as recom-
mended by the company. Two standards (1.5 × 10−1 ng/µL)
were included in each experiment, and the generated exter-
nal standard curve was imported for quantification. All P.
jirovecii–positive samples and a randomly selected sub-
group of P. jirovecii–negative samples (all negative sam-
ples from patients born on the first through third days of
the month) were assayed; 5 µL of patient specimen or the
standard dilution was added per tube.
Interpretation 
If a PCR-positive sample was negative by the second
analysis, the sample was reextracted and reassayed in 2
tubes. If at least 2 of 4 tubes were positive, the sample was
recorded as positive for P. jirovecii.
A negative MSG result had to have a positive result
for the internal control to be considered valid, to ensure
absence of inhibitors in the specimen. If PCR inhibitors
were detected, the sample was to be diluted 1:5.
Data Analysis 
All acquired fluorescence data were analyzed with
LightCycler software (Roche). Clinical data were recorded
with EpiData 2.1a (EpiData Association, Odense,
Denmark). Statistics were calculated by using the SAS
System, version 9.1 for Windows (SAS Institute Inc., Cary,
NC, USA).
Wilcoxon 2-sample test or Kruskal-Wallis test was
used to compare quantitative data when appropriate. Fisher
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of <0.05 was considered significant. Values presented are
medians with ranges or interquartile ranges (IQR).
Logistic regression was used for univariate and multivari-
ate analyses.
Results
Patients and Episodes 
Four hundred sixty-one NPAs from 423 patients with
432 episodes were available for analysis. One HIV-infect-
ed child with PCP was excluded from analysis. The
remaining infants were presumed to be uninfected with
HIV of the basis of review of their medical charts. Two
hundred ninety-six (70%) patients (with 303 episodes
[70%]) were hospitalized at Hvidovre University Hospital
and the rest at Amager Hospital. Sixty-four percent of the
episodes received a diagnosis of LRTI, 28% a diagnosis of
URTI, and 8% “other.” The median age was 112 days (IQR
49–265), and 52.7% of the NPAs were from male patients.
PCR Results
No samples exhibited inhibition. All controls were
appropriate. Sixty-seven (16%) of the 422 patients had
positive test results for P. jirovecii in 68 (16%) of 431
episodes. More than 1 NPA was collected in 21 episodes,
of which 4 (19%) were P. jirovecii positive, and PCR
results were concordant in 96% (46/48 samples) of the
NPAs. NPAs from 8 pairs of siblings were collected, and
all pairs were concordant (1/8 pairs positive).
Basic demographic data for the P. jirovecii–positive
and –negative groups are presented in Table 1, and age dis-
tribution in quartiles is presented in Table 2. Significant dif-
ferences were found in age, days admitted to hospital, and
occurrence of reported fever. However, no significant dif-
ference was found in temperature at admission. No differ-
ence in positivity rate was seen between the 2 hospitals.
Univariate and multivariate analyses are presented in  Table
3. By univariate analysis, URTI versus LRTI, age quartiles
2 and 3 versus 1, and reported fever were associated with
the presence of P. jirovecii, but days admitted to the hospi-
tal was not. Age quartiles 2 and 3 versus quartile 1 and
URTI versus LRTI were independently associated with P.
jirovecii positivity by multivariate analysis. The distribu-
tion of number of episodes by clinical diagnosis and age is
illustrated by online Appendix Figure A (available from
www.cdc.gov/ncidod/EID/13/1/66-appG.htm#A) and the
frequency of P. jirovecii–positive episodes by online
Appendix Figure B (available from www.cdc.gov/ncidod/
EID/13/1/66-appG.htm#B).
Quantitative Analysis of PCR-positive Results
If >1 NPAs were collected during the same episode,
average numbers of copies were calculated for that
episode. The P. jirovecii–positive episodes had a median of
9 copies/tube (IQR 2.8–25).
Of the 387 P. jirovecii–negative NPAs, 49 (12.7%)
were randomly selected for betaglobin analysis. The P.
jirovecii–positive and –negative samples had a median of
129,400 (IQR 49,540–298,800) versus 95,410 (IQR
27,610–228,800) pg/tube, with no significant difference
(p = 0.09).
Due to the natural variation of the specimens, P.
jirovecii copy numbers were corrected for amount of
human DNA in the sample (copies MSG per ng betaglo-
bin). The PCR-positive episodes had a median of 0.069
(IQR 0.021–0.315) copies/ng betaglobin per tube.
The quantitative data were normally distributed when
logarithm transformed (Figure). Quantitative data for age
and clinical diagnosis subgroups are presented in Table 4.
No significant differences were found among groups.
Discussion
In this study, P. jirovecii was detected in NPAs from
16% of infants hospitalized with acute RTI. A marked dif-
ference occurred in the age distribution, as the prevalence
was 48% in infants ages 50 to 112 days (second quartile),
13% in infants ages 113 to 265 days (third quartile), and
negligible in the youngest and oldest infants (Table 2,
online Appendix Figure). Similarly, ORs of 47 and 8.7
were found for the second and third quartiles, respectively,
when compared with that of the youngest group for being
P. jirovecii positive by multivariate analysis (Table 3).
These data indicate that infants were exposed very early to
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diagnosis should be considered in infants ages 1.5–4
months who exhibit symptoms of an acute RTI.
The relative absence of P. jirovecii among the
youngest infants (ages <50 days) could indicate either dif-
ferences in exposure or in immunity, or reflect the incuba-
tion time of the infection. One could hypothesize that the
increased rate of P. jirovecii positivity was coincidental
with the infants’ introduction to a daycare facility/institu-
tion. However, the infants were cared for at home and not
at an institution in 64 (96%) of the 67 P. jirovecii–positive
episodes.
Another possible explanation is differences in immu-
nity, which could be mediated by maternal antibodies in
the youngest infants. Animal studies have shown that
maternal antibodies are protective in infants (15–17).
Likewise,  P. jirovecii was seldom found in the oldest
infants (>265 days of age), which may have been due to
acquired immunity. Previous studies suggest that the clear-
ance of organisms is complete; no detectable organisms
were found by microscopy or PCR in postmortem lung
specimens from immunocompetent adult patients (18).
However, primary infection could possibly be acquired
later in life and produce a milder illness (one that does not
require hospitalization) in older children, and therefore
these cases are not included in the current study.
Also, the absence of P. jirovecii among the youngest
infants (ages <50 days) may have been a result of the incu-
bation period of the infection, assuming that organism bur-
den during the incubation period was below level of
detection of the assay. Animal studies have indicated that
the peak organism load in healthy mice occurs 5–6 weeks
after exposure (19,20). Thus, the infants could have been
exposed shortly after birth in order for symptoms to devel-
op in infants at the ages found here. In fact, animal studies
have found early exposure of newborn infants by a mater-
nal source, and asymptomatic carriage by pregnant women
has been reported recently (21–23). In a reported case of
probable mother-to-infant transmission, the mother
became symptomatic at 3 days postpartum and the infant
at 29 days of age (24). The shorter incubation period in this
case may reflect a higher level of infectious inoculum in
this infant.
The age distribution was in concordance with the
trend reported in a recent study on autopsied lung speci-
mens from 112 infants (25). Similarly, serologic studies
have indicated that most children seroconvert early in life
(2–5,8,26). Among children with perinatally acquired HIV,
the incidence of PCP was highest from 3 to 6 months of
age (27,28). That is, these infants were slightly older when
PCP was diagnosed. Assuming that they were exposed to
P. jirovecii at the same time as healthy infants, the differ-
ence could be because a longer incubation time is needed
for clinical PCP to develop in susceptible immunocompro-
mised persons. Previous studies have reported an overall P.
jirovecii prevalence of 25% (8), and 32% (9) in infants
with acute RTI. When episodes were considered, however,
the prevalence in the latter study was 17%, which was in
concordance with the findings in our current study. The
former study comprised 178 infants but did not include
clinical data, and the latter study comprised a smaller pop-
ulation (74 infants with 178 episodes). Geographic varia-
tion or methodologic differences may account for the
slight difference in reported prevalence. Our study used a
single-round, closed-tube, PCR format for detection,
which has a high sensitivity and a greatly reduced risk for
carryover contamination (14). The difference in amount of
human DNA detected in P. jirovecii–positive and –nega-
tive samples did not reach the 5% level of significance. If,
in fact, a difference exists, this could be because sample
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mated the true prevalence of P. jirovecii carriage. The dif-
ference could also have occurred because the presence of
P. jirovecii increases the amount of, for example, inflam-
matory cells in the nasopharyngeal secretions (29), there-
by increasing the amount of human DNA sampled. The
current study confirms the previous reports that P. jirovecii
can be detected in respiratory tract specimens from other-
wise healthy infants with an acute RTI.
Pneumocystis is likely transmitted through the respira-
tory route (30). The reservoir for P. jirovecii is unknown
but could include other persons or environmental sources,
whereas animal reservoirs are unlikely because of the host
specificity (6,31). Animal studies have shown that colo-
nized mice may transmit the organism to immunosup-
pressed mice (32). Therefore, healthy children with a
primary P. jirovecii infection may play a role in the circu-
lation of the organism as previously suggested (25),
although recent genotyping studies have yielded conflict-
ing results (10,33).
P. jirovecii–positive episodes could represent either
colonization or clinical overt disease. We have previously
shown the assay used here provides reproducible quanti-
tative results, and that a similar real-time quantitative
PCR assay correlates well with the number of whole
organisms in the sample (14,34). The fact that the quanti-
tative data were normally distributed after logarithmic
transformation (Figure), and that no differences in copy
numbers were detected among groups (Table 4), may indi-
cate that the P. jirovecii–positive episodes represent 1 bio-
logic phenomenon.
To our knowledge, no previous evidence has shown a
connection between clinical illness or specific symptoms
and primary infection in immunocompetent children. It has
been presumed to be an asymptomatic or mild, nonspecif-
ic disease (6,22). In the study by Vargas et al., no differ-
ences in clinical diagnosis were observed (8). In the
current study, we found that infants with an episode of
URTI were 2.0× more likely to be carrying P. jirovecii than
infants with LRTI, when findings were adjusted for age
(online Appendix Figure B, Table 3). This finding is some-
what surprising because the organism causes LRTI in
immunocompromised subjects. It is unlikely that the find-
ing is due to differences in sample quality, because the
amount of betaglobin detected in samples from patients
with URTI and LRTI was similar (data not shown), and no
difference in adjusted Pneumocystis DNA was detected
(Table 4). Parents reported that the child had a history of
fever less often in P. jirovecii–positive episodes by univari-
ate analysis, but no differences were found in the presence
of fever as assessed at admission (Tables 1 and 3). Also, P.
jirovecii–positive infants tended to be hospitalized for a
marginally shorter duration (Tables 1 and 3).
The limitations of this study are primarily the lack of
a healthy control group without respiratory symptoms, and
lack of serologic data from the patients. Also, a compre-
hensive analysis of the specimens was not done for known
respiratory pathogens other than RSV and P. jirovecii.
Further investigation is therefore needed to confirm these
findings before recommendations can be made for routine
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Figure. Plot of logarithmic transformed values of copies/ng beta-
globin detected in PCR-positive tubes (c). Solid line denotes nor-
mal distribution.diagnostic testing for Pneumocystis in defined populations
of infants, because it remains possible that Pneumocystis
carriage in this population could represent a bystander phe-
nomenon. Similarly, one should be cautious in inferring
these results to infants without RTI or to those with an RTI
that does not require hospitalization.
In this study, we found an overall prevalence of P.
jirovecii in the respiratory tracts of 16% of infants hospi-
talized with an episode of acute RTI. Infants ages 50–112
days harbored P. jirovecii in 48% of the episodes. Our data
suggest that primary P. jirovecii infection acquired early in
life may present itself as a self-limiting URTI.
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